Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group Limited has confirmed that its planned disposal of a 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd. has been approved by the shareholders of the vendor entity. With this shareholder approval secured, the connected transaction will now move toward completion under the terms set out in the equity transfer agreement.
The move signals CSPC’s continued portfolio adjustment and capital reallocation strategy involving a connected party, which may refine the group’s investment structure and focus. Stakeholders will watch the completion of this disposal for its implications on CSPC’s financial profile, governance of related-party interests, and flexibility for future strategic initiatives.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the development, manufacturing, and sale of medicines and related healthcare products. Listed on the Hong Kong Stock Exchange, it operates under stock code 1093 and is overseen by a board comprising executive and independent non-executive directors.
Average Trading Volume: 113,135,463
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$111.7B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.